Construction of a Tumor Mutational Burden-derived LncRNA Prognostic Computational Framework Associated with Therapy Sensitivity in Skin Cutaneous Melanoma

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2024 Oct 25

PMID 39449143

Authors

Gaohua Li

Tingting Wu

Heping Li

Chuzhong Wei

Yuanbo Sun

Pengcheng Gao

Xinlin Huang

Zining Liu

Jianwei Li

Yanan Wang

Guoxin Li

Lei Fan

Affiliations

Soon will be listed here.

Abstract

Background: Skin cutaneous melanoma (SKCM) poses a significant public health challenge due to its aggressive nature and limited treatment options. To address this, the study introduces the Tumor Mutational Burden-Derived Immune lncRNA Prognostic Index (TILPI) as a potential prognostic tool for SKCM.

Methods: TILPI was developed using a combination of gene set variation analysis, differential expression analysis, and COX regression analysis. Additionally, functional experiments were conducted to validate the findings, focusing on the effects of STARD4-AS1 knockdown on SKCM tumor cell behavior. These experiments encompassed assessments of tumor cell proliferation, gene and protein expression, migration, invasion, and in vivo tumor growth.

Results: The results demonstrated that knockdown of STARD4-AS1 led to a significant reduction in tumor cell proliferation and impaired migration and invasion abilities. Moreover, it resulted in the downregulation of ADCY4, PRKACA, and SOX10 gene expression, as well as decreased protein expression of ADCY4, PRKACA, and SOX10. In vivo experiments further confirmed the efficacy of STARD4-AS1 knockdown in reducing tumor growth.

Conclusions: This study elucidates the mechanistic role of STARD4-AS1 and its downstream targets in SKCM progression, highlighting the importance of the ADCY4/PRKACA/SOX10 pathway. The integration of computational analysis with experimental validation enhances the understanding of TILPI and its clinical implications. Overall, the findings underscore the potential of novel computational frameworks like TILPI in predicting and managing SKCM, particularly through targeting the ADCY4/PRKACA/SOX10 pathway.

References

Reijers I, Menzies A, van Akkooi A, Versluis J, van den Heuvel N, Saw R . Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022; 28(6):1178-1188. DOI: 10.1038/s41591-022-01851-x. View

Wei C, Zhu M, Lu N, Liu J, Yang Y, Zhang Y . Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p/CXCL12 axis in melanoma. Mol Cancer. 2020; 19(1):84. PMC: 7204052. DOI: 10.1186/s12943-020-01191-9. View

Liu J, Luo B, Zhang P, Jiang K, Hou Z, Cao X . Necroptosis-related LncRNAs in skin cutaneous melanoma: evaluating prognosis, predicting immunity, and guiding therapy. BMC Cancer. 2023; 23(1):752. PMC: 10424397. DOI: 10.1186/s12885-023-11246-x. View

Chan T, Yarchoan M, Jaffee E, Swanton C, Quezada S, Stenzinger A . Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2018; 30(1):44-56. PMC: 6336005. DOI: 10.1093/annonc/mdy495. View

Becht E, Giraldo N, Lacroix L, Buttard B, Elarouci N, Petitprez F . Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17(1):249. PMC: 5134277. DOI: 10.1186/s13059-016-1113-y. View

Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T . Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018; 109(7):2093-2100. PMC: 6029823. DOI: 10.1111/cas.13642. View

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

Tian C, Liu S, Huo R . Identification of the ageing-related prognostic gene signature, and the associated regulation axis in skin cutaneous melanoma. Sci Rep. 2023; 13(1):24. PMC: 9834281. DOI: 10.1038/s41598-022-22259-0. View

Racle J, de Jonge K, Baumgaertner P, Speiser D, Gfeller D . Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017; 6. PMC: 5718706. DOI: 10.7554/eLife.26476. View

10.

Bhave P, Ahmed T, Lo S, Shoushtari A, Zaremba A, Versluis J . Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. J Immunother Cancer. 2022; 10(7). PMC: 9260790. DOI: 10.1136/jitc-2022-004668. View

11.

Fusco M, West H, Walko C . Tumor Mutation Burden and Cancer Treatment. JAMA Oncol. 2020; 7(2):316. DOI: 10.1001/jamaoncol.2020.6371. View

12.

Sturm G, Finotello F, Petitprez F, Zhang J, Baumbach J, Fridman W . Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics. 2019; 35(14):i436-i445. PMC: 6612828. DOI: 10.1093/bioinformatics/btz363. View

13.

Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

14.

Yang L, Lu P, Yang X, Li K, Chen X, Qu S . Excavating novel diagnostic and prognostic long non-coding RNAs (lncRNAs) for head and neck squamous cell carcinoma: an integrated bioinformatics analysis of competing endogenous RNAs (ceRNAs) and gene co-expression networks. Bioengineered. 2021; 12(2):12821-12838. PMC: 8810019. DOI: 10.1080/21655979.2021.2003925. View

15.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

16.

Ellrott K, Bailey M, Saksena G, Covington K, Kandoth C, Stewart C . Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 2018; 6(3):271-281.e7. PMC: 6075717. DOI: 10.1016/j.cels.2018.03.002. View

17.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

18.

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

19.

Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H . Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019; 11(1):34. PMC: 6534875. DOI: 10.1186/s13073-019-0638-6. View

20.

Kalaora S, Nagler A, Wargo J, Samuels Y . Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer. 2022; 22(4):195-207. DOI: 10.1038/s41568-022-00442-9. View